• XNK Therapeutics
    appoints Michael Uhlin as
    Chief Scientific Officer

  • XNK Therapeutics Reports First Patient
    Included in Phase II Study
    in Multiple Myeloma

XNK Therapeutics

Individualized NK Cell Therapies

XNK Therapeutics AB is an immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company’s platform-technology and leading investigational autologous drug candidate, CellProtect, has ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies.

Product

The company owns assets related to the clinical use of the investigational drug product, CellProtect, and its manufacturing technology.

Clinical trial

CellProtect, autologous ex vivo expanded and activated NK cells with potent anti-cancer activity, is the company’s lead investigational drug candidate. CellProtect is intended to be utilized in specialized clinic as well as in open-care settings.